Fatal HBV reactivation in a subject with anti-HBs and anti-HBc

Internal Medicine

Volumn 45, Issue 12, 2006, Pages 747-748

  Umemura, Takeji ^a   Kiyosawa, Kendo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fulminant hepatitis; Hepatitis B virus; Reactivation; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; RITUXIMAB; VIRUS DNA;

B LYMPHOCYTE; CAUSE OF DEATH; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; FATALITY; GENOTYPE; HEPATITIS B; HUMAN; INCIDENCE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTE DEPLETION; LYMPHOMA; MORTALITY; MUTATIONAL ANALYSIS; PROMOTER REGION; RISK ASSESSMENT; SEROCONVERSION; VIRUS CARRIER; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; VIRUS ACTIVATION;

EID: 33746349885     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.0158     Document Type: Editorial

References (15)

1. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.
2. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy pathogenesis and management. Rev Mod Virol 11: 287-299, 2001.
3. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2: 1104-1108, 1996.
4. Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37: 1172-1179, 2003.
5. Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006 (in press).
6. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45 (11): 721-724, 2006.
7. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344: 68-69, 2001.
8. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 68: 292-294, 2001.
9. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102: 1930, 2003.
10. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83: 58-60, 2004.
11. Suzan F, Ammor M, Ribrag V, et al. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345: 1000, 2001.
12. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96: 1184-1186, 2000.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 39: 857-861, 2004.
14. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105-112, 1975.
15. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188, 1991.